Description
Background:
Thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, are associated with injury and dysregulation of microvascular endothelium and platelets.1 Evidence increasingly points to a role for the complement system in TMA.Mannan-associated lectin-binding serine protease-2 (MASP-2) is a major effector in the complement lectin pathway.Narsoplimab (OMS721), a human IgG4 anti-MASP-2 antibody, is under consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and IgA nephropathy. Narsoplimab is under investigation in clinical trial NCT03205995 (Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome).
Intended Use:
For Estimation of Narsoplimab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!